Hunan Hansen Pharmaceutical Co Ltd - Asset Resilience Ratio
Hunan Hansen Pharmaceutical Co Ltd (002412) has an Asset Resilience Ratio of 13.94% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Hunan Hansen Pharmaceutical Co Ltd (002412) financial obligations for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2021–2024)
This chart shows how Hunan Hansen Pharmaceutical Co Ltd's Asset Resilience Ratio has changed over time. See Hunan Hansen Pharmaceutical Co Ltd shareholders equity for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Hunan Hansen Pharmaceutical Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Hunan Hansen Pharmaceutical Co Ltd market cap and net worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥357.16 Million | 13.94% |
| Total Liquid Assets | CN¥357.16 Million | 13.94% |
Asset Resilience Insights
- Moderate Liquidity: Hunan Hansen Pharmaceutical Co Ltd has 13.94% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company has significant short-term investments, indicating active treasury management.
Hunan Hansen Pharmaceutical Co Ltd Industry Peers by Asset Resilience Ratio
Compare Hunan Hansen Pharmaceutical Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Daihan Pharmaceutical Co.Ltd
KQ:023910 |
Drug Manufacturers - Specialty & Generic | 11.95% |
|
Aurobindo Pharma Limited
NSE:AUROPHARMA |
Drug Manufacturers - Specialty & Generic | 16.92% |
|
China Resources Sanjiu Medical & Pharmaceutical Co Ltd
SHE:000999 |
Drug Manufacturers - Specialty & Generic | 5.22% |
|
Ningbo Menovo Pharm Co Ltd
SHG:603538 |
Drug Manufacturers - Specialty & Generic | 2.69% |
|
Zhejiang Xianju Pharmaceutical Co Ltd
SHE:002332 |
Drug Manufacturers - Specialty & Generic | 6.02% |
|
Qianjiang Yongan Pharmaceutical Co Ltd
SHE:002365 |
Drug Manufacturers - Specialty & Generic | 30.38% |
|
Hainan Honz Pharmaceutical Co
SHE:300086 |
Drug Manufacturers - Specialty & Generic | 0.27% |
|
Guangdong Lifestrong Pharmacy Co. Ltd.
SHE:301111 |
Drug Manufacturers - Specialty & Generic | 7.85% |
Annual Asset Resilience Ratio for Hunan Hansen Pharmaceutical Co Ltd (2021–2024)
The table below shows the annual Asset Resilience Ratio data for Hunan Hansen Pharmaceutical Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 9.58% | CN¥244.12 Million ≈ $35.72 Million |
CN¥2.55 Billion ≈ $372.74 Million |
+0.86pp |
| 2023-12-31 | 8.73% | CN¥203.87 Million ≈ $29.83 Million |
CN¥2.34 Billion ≈ $341.90 Million |
+2.80pp |
| 2022-12-31 | 5.93% | CN¥135.82 Million ≈ $19.87 Million |
CN¥2.29 Billion ≈ $335.24 Million |
+3.60pp |
| 2021-12-31 | 2.33% | CN¥49.24 Million ≈ $7.21 Million |
CN¥2.11 Billion ≈ $308.95 Million |
-- |
About Hunan Hansen Pharmaceutical Co Ltd
Hunan Hansen Pharmaceutical Co., Ltd. engages in the production and sale of traditional Chinese preparations in China and internationally. The company offers digestive system medicines; cardiovascular and cerebrovascular medicines; kidney-tonifying and urine-reducing medicines; trauma medicines; diagnostic medicines, etc. It provides medicines in injection, mixture, tablet, capsule, granule, syru… Read more